Treats infections caused by susceptible strains of the designated microorganisms in the…. ANDA 77568, held by FDC. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 77568 (Ciprofloxacin Hydrochloride), held by FDC, was first approved by FDA on Jun 30, 2008, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Ciprofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ciprofloxacin HydrochlorideEQ 0.3% BASE · solution/drops;ophthalmic | Ciprofloxacin Hydrochloride | Rx |
| Mar 16, 2015 | Supplement 6Labeling | Approved | None posted |
| Jun 30, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters